Medical Marijuana, Inc. (OTC:MJNA), the first publicly traded cannabis company in the United States, today announced that an executive from its subsidiary HempMeds® Brasil spoke on the benefits of cannabidiol (CBD) hemp oil at the Fourth International Congress of Neuroscience at the Albert Einstein Hospital in São Paulo, Brazil on Oct. 5, 2018.
“Participating in the International Congress of Neuroscience allows us to connect with medical professionals throughout Brazil and offer important education on the benefits of CBD,” said Medical Marijuana, Inc. CEO Dr. Stuart Titus. “Supporting CBD research and education throughout the world is one of our top priorities and we’re honored to be a trusted resource for the Brazilian community.”
The event venue, the Albert Einstein Hospital, is one of the most modern private hospitals in Latin America, boasting more than six thousand registered doctors. It was the first health institution outside the United States to be certified by the Joint Commission International.
HempMeds® Brasil Director of Medical Affairs Junior S. Gibelli spoke during the event and educated doctors about CBD as a supplement for both children and adults. Some of the most highly regarded Brazilian doctors and healthcare professionals attended and received new information about breakthroughs in cannabis research during this presentation.
“We are thrilled to receive the opportunity to speak at one of the best private medical institutions in Latin America and speak directly with top doctors who are looking to prescribe CBD to their patients,” said HempMeds® Brasil Vice President Caroline Heinz. “We trust that the doctors who attended the event were able to take home valuable information and relay it to their hospital administrators and patients.”
HempMeds® Brasil was the first company to receive an import permit for CBD in Brazil and, after a series of historic rulings, Brazilian Health Regulatory Agency ANVISA removed CBD from Brazil’s prohibited substance use list, removed the substance’s import tax and is now actively subsidizing the cost of CBD for those who need financial assistance.
To learn more about the event, please visit https://hempmeds.com.br/.
About Medical Marijuana, Inc.
We are a company of firsts®. Our mission is to be the premier cannabis and hemp industry innovators, leveraging our team of professionals to source, evaluate and purchase value-added companies and products, while allowing them to keep their integrity and entrepreneurial spirit. We strive to create awareness within our industry, develop environmentally-friendly, economically sustainable businesses, while increasing shareholder value. For details on Medical Marijuana, Inc.’s portfolio and investment companies, visit www.medicalmarijuanainc.com.
To see Medical Marijuana, Inc.’s corporate video, click here.
Shareholders and consumers are also encouraged to buy CBD oil and other products at Medical Marijuana, Inc.’s shop.
About HempMeds® Brasil
HempMeds® Brasil was the first company to receive approval from the National Sanitary Surveillance Agency (Anvisa) to import a product based on cannabidiol, a substance derived from hemp, a plant of the genus Cannabis. Currently, it is authorized to supply its products, which help in the control of diseases such as epilepsy, Parkinson’s, chronic pain and multiple sclerosis, under medical prescription. For these indications, the products can be subsidized by the Brazilian government. HempMeds® Brasil works on additional approvals for other indications. www.hempmeds.com.br.
This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of Medical Marijuana, Inc. to be materially different from the statements made herein.
FOOD AND DRUG ADMINISTRATION (FDA) DISCLOSURE
These statements have not been evaluated by the FDA and are not intended to diagnose, treat or cure any disease.
Medical Marijuana, Inc. does not sell or distribute any products that are in violation of the United States Controlled Substances Act (US.CSA). These companies do grow, sell, and distribute hemp-based products and are involved with the federally legal distribution of medical marijuana-based products within certain international markets. Cannabidiol is a natural constituent of hemp oil.
CONTACT:Public Relations Contact: Andrew Hard Chief Executive Officer CMW Media P. 858-264-6600 email@example.com www.cmwmedia.com
View original content to download multimedia:http://www.prnewswire.com/news-releases/medical-marijuana-inc-subsidiary-hempmeds-brasil-speaks-at-fourth-international-congress-of-neuroscience-in-sao-paulo-brazil-300730518.html
SOURCE Medical Marijuana, Inc.